Share chart FibroGen
Extended chart
Simple chart
About FibroGen
FibroGen, Inc.- научная фармацевтическая компания, специализирующаяся на открытии, разработке и коммерциализации новых терапевтических агентов для лечения серьезных медицинских заболеваний. Компания использует глобальный подход к разработке и коммерциализации своих продуктов.| IPO date | 2014-11-14 |
|---|---|
| ISIN | US31572Q8087 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | https://www.fibrogen.com |
| Цена ао | 0.343 |
| Change price per day: | +0.1168% (0.3426) |
|---|---|
| Change price per week: | -4.11% (0.3577) |
| Change price per month: | -40.88% (0.5802) |
| Change price per 3 month: | -31.21% (0.4986) |
| Change price per half year: | -12.41% (0.3916) |
| Change price per year: | -86.71% (2.58) |
| Change price per 3 year: | -96.87% (10.96) |
| Change price per 5 year: | -99.17% (41.36) |
| Change price per 10 year: | -98.45% (22.18) |
| Change price per year to date: | -31.21% (0.4986) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| PRIMECAP Management Company | 14471928 | 14.65 |
| Armistice Capital, LLC | 9764000 | 9.89 |
| Blackrock Inc. | 7205300 | 7.29 |
| Vanguard Group Inc | 7044149 | 7.13 |
| Jacobs Levy Equity Management, Inc. | 2489506 | 2.52 |
| Acadian Asset Management. LLC | 2468928 | 2.5 |
| Citadel Advisors Llc | 2390681 | 2.42 |
| Assenagon Asset Management S.A. | 2226857 | 2.25 |
| Two Sigma Investments, LP | 2101283 | 2.13 |
| Geode Capital Management, LLC | 2018281 | 2.04 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| ProShares UltraShort Nasdaq Biotechnology | 0.47 | -40.36 | 1.76 |
| FlexShares Morningstar Emerging Markets Factor Tilt Index Fund | 0.02077 | 12.46 | 3.59676 |
| SPDR S&P Emerging Markets Small Cap ETF | 0.01204 | 5.46 | 3.03583 |
| iShares Micro-Cap ETF | 0.01029 | 17.09 | 1.54048 |
| Avantis Emerging Markets Value ETF | 0.00067 | 14.12 | 4.22231 |
Vanguard FTSE All-World ex-US Small-Cap ETF
|
0 | 9.39 | 3.09932 |
| 0.09 | 3.03 | 2.88 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Thane Wettig | CEO & Director | 807.35k | 1965 (60 years) |
| Dr. Barry A. Berkowitz Ph.D. | Founder | N/A | |
| Dr. John J. Hunter Ph.D. | Chief Scientific Officer | N/A | 1963 (62 years) |
| Ms. Christine L. Chung | Senior Vice President of China Operations | 1.27M | 1968 (57 years) |
| Mr. Michael D. Lowenstein J.D., Ph.D. | Chief Legal Officer | N/A | |
| Ms. Tricia Stewart | Chief People Officer | N/A | |
| Mr. Kirk A. Christoffersen MBA | Chief Business Officer | N/A | 1969 (56 years) |
| Dr. Rahul Rajan Kaushik Ph.D. | Senior Vice President of Pharmaceutical Development, Technical Operations & Manufacturing | N/A | |
| David DeLucia | Vice President of Corporate FP&A and Investor Relations | N/A | |
| Mr. Juan Graham | Senior VP & CFO | 1976 (49 years) |
Address: United States, San Francisco, CA , 409 Illinois Street - open in Google maps, open in Yandex maps
Website: https://www.fibrogen.com
Website: https://www.fibrogen.com
